Tolga Tanguler Sells 1,598 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the transaction, the executive vice president owned 36,606 shares of the company’s stock, valued at $11,993,955.90. The trade was a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tolga Tanguler also recently made the following trade(s):

• On Friday, February 13th, Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total transaction of $607,446.72.
• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $320.51 on Friday. The stock has a market capitalization of $42.51 billion, a price-to-earnings ratio of 187.43 and a beta of 0.36. The company has a fifty day moving average of $353.84 and a 200 day moving average of $415.74. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.65) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Groupama Asset Managment boosted its holdings in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $895,816,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $369,943,000. Finally, Holocene Advisors LP purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $194,616,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ALNY shares. Royal Bank Of Canada reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a report on Friday, January 30th. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Needham & Company LLC reduced their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease; the deal includes upfront cash and research funding plus up to $1.13 billion in milestone payments, expanding Alnylam’s RNAi pipeline into a large disease area. Read More.
• Positive Sentiment: Coverage notes a reimbursement win and reported trial progress for Alnylam’s programs — improving near‑term commercial visibility for approved RNAi medicines and supporting revenue upside against current valuation. Read More.
• Positive Sentiment: Industry backdrop remains supportive: market reports project strong growth for orphan drugs, which underpins long‑term demand for Alnylam’s rare‑disease franchises. Read More.
• Neutral Sentiment: Short‑interest figures in recent reports show zero shares and a 0.0 days‑to‑cover — this appears to be a reporting glitch and is unlikely to represent a real change in short positioning.
• Neutral Sentiment: Analyst coverage remains mixed to favorable with a consensus “Moderate Buy” and a wide range of price targets; useful context for longer‑term expectations but not an immediate driver.
• Negative Sentiment: Significant clustered insider selling: CEO Yvonne Greenstreet reported selling ~6,799 shares (~$2.23M) and multiple EVPs sold 1.6k–2.2k shares each across March 2–3. These concurrent executive sales (disclosed in SEC filings and insider summaries) can create short‑term negative sentiment and add selling pressure despite insiders retaining large holdings. Read More. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.